氯诺昔康联合间苯三酚治疗胆囊结石致急性腹痛的Meta分析

doi:10.3969/j.issn.1006-5253.2018.01.001

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (1632 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the efficacy and safety of lornoxicam and phloroglucinol treating acute abdominal pain in patients with gallstone. Methods The randomized controlled studies (RCTs) of lornoxicam and phloroglucinol treating acute abdominal pain in patients with gallstone were conducted. Two reviewers independently screened the literatures, extracted data and evaluated the quality of studies. Meta analysis was performed by Revman 5.3 software. Results Compared with the phloroglucinol group (the control group), incidence of adverse drug reactions in the lornoxicam and phloroglucinol group (the combined group) had no significant difference (RR=0.82,95%CI:0.49~1.39, P=0.47). Pain relief time (MD=-28.77,95%CI:-30.39~-27.15, P<0.001), 1H-VAS (MD=-1.88,95%CI:-2.05~ -1.71, P<0.001) and pain recurrence rate (RR=0.46,95%CI:0.28~0.62, P<0.001) in the combined group were significantly better than those in the control group. Conclusion From this systematic review, lornoxicam and phloroglucinol treating acute abdominal pain in patients with gallstone is safe and effective. But there are some limitations in this study, which still need to be validated with traditional drug control, good design, multi centers and large scale clinical randomized controlled study.

Key words： lornoxicam phloroglucinol acute abdominal pain gallstone meta analysis

Received: 31 August 2017

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yao Lili
	Sun Chengfan
	Yu Jianhua
	Xu Jinlong

Cite this article:

Yao Lili,Sun Chengfan,Yu Jianhua, et al. Meta analysis on lornoxicam and phloroglucinol treating acute abdominal pain in patients with gallstone[J]. journal1, 2018, 25(1): 1-4.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2018.01.001 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2018/V25/I1/1

[1] 中华医学会麻醉学分会.成人手术后疼痛处理专家共识[J].临床麻醉学杂志,2017,33(9):911-917.
[2] 瞿浩,夏玮.氯诺昔康的药理及临床应用[J].山东医药,2011,51(29):112-113.
[3] 田渊,王智勇,张志强.全膝关节置换后镇痛:超前和多模式联合镇痛的比较[J].中国组织工程研究,2015,19(44):7108-7113.
[4] 袁智,牟哲,袁裘文,等.氯诺昔康片对痛风性关节炎镇痛效果及安全性观察[J].中国医药导报,2014,11(24):84-86.
[5] 方宝霞,刘杰,刘慧敏,等.曲马多联合氯诺昔康术后静脉自控镇痛疗效与安全性的Meta分析[J].安徽医药,2013,17(9):1564-1567.
[6] 赵红霞,吴刚,滕云鹏,等.舒芬太尼联合氯诺昔康对术后静脉自控镇痛的效果观察[J].西北药学杂志,2016,31(4):426-428.
[7] 罗继文,田文华,高嵩.氯诺昔康联合地佐辛对开胸手术全麻苏醒期躁动的预防效果研究[J].中国医院药学杂志,2017,37(11):1082-1084.
[8] 赵红,叶铁虎,龚志毅.氯诺昔康用于全子宫切除术后患者自控镇痛的非劣效性[J].北京大学学报(医学版),2013,45(1):119-122.
[9] 李健和,易利丹,彭六保,等.间苯三酚的药理作用与临床应用[J].中国新药与临床杂志,2011,30(7):494-499.
[10]叶萍,李兆坤,邹多武.间苯三酚注射液治疗痉挛性腹痛的临床观察[J].第二军医大学学报,2002,23(4):390-392.
[11]李影,俞富祥,叶媛媛,等.间苯三酚在急诊胆绞痛治疗中的应用[J].温州医科大学学报,2016,46(3):220-222.
[12]朱雅丽,杨元生.氯诺昔康、间苯三酚联合治疗胆囊结石所致急性腹痛的疗效[J].中国医药指南,2012,10(19):65-66.
[13]李朝信.氯诺昔康、间苯三酚联合治疗胆囊结石所致急性腹痛的临床疗效观察[J].北方药学,2015,12(10):55.
[14]尹扬光,史忠,唐永岗,等.氯诺昔康联合间苯三酚治疗胆囊结石所致急性腹痛的疗效观察[J].西南国防医药,2010,20(4):390-392.
[15]徐志刚.氯诺昔康联合间苯三酚治疗胆囊结石所致急性腹痛的疗效评价[J].海峡药学,2016,28(4):171-172.
[16] 赵淑桂.氯诺昔康联合间苯三酚治疗胆囊结石所致急性腹痛的疗效评价[J].中国医药指南,2014,12(6): 91-92.
[17]王海哨.氯诺昔康2例严重不良反应及原因分析[J].中外医疗,2011,(24):77-77.
[18]BOZIMWSKI G.A review of nonsteroidal anti-inflammatory drugs[J]. AANA J, 2015,83(6):425-433.
[19]马超,崔喜凤,张树荣,等.注射用氯诺昔康所致不良反应的相关因素和帕累托图分析[J].中国药事,2017,31(7):807-813.
[20]郑彦云,王莉,徐峰,等. 氯诺昔康的不良反应及其合理使用的回顾性调查[J].中国药业,2003,12(12):67-68.
[21]崔喜凤,邢丽秋,马超,等. 北京地区氯诺昔康致不良反应48例分析[J].中国药房,2015,26(32):4523-4525.